There are currently 6 medications (orlistat, naltrexone-bupropion, liraglutide, semaglutide, tirzepatide, and phentermine-topiramate) that have been approved for the treatment of obesity in adults [8, 9]
Several mechanisms have been implicated in the pathophysiology of diabetes-induced OA
At the highest dose, participants lost an average of 24.2% weight in 11 months, which is far superior to the 15-20% weight loss effect of other GLP-1 receptor agonists currently on the market (such as Semaglutide and Tirzepatide)
Foundayo: Comparing the First 2 GLP-1 Weight Loss Pills Until recently, glucagon-like peptide-1 (GLP-1) receptor agonists were only available as an injection
This tells you what stuck and what bounced back
Study Reference Coy DH, Hocart SJ, Murphy WA